🐦 推特Wall St EngineCodex · 实盘不做把握 8/10
北京时间·🕒 发布 18:28:34时区推断·⟳ 抓取 18:29:00·⚡ 决策 08-04 18:31:08 +2m08s·84.3 天前
Revvity二季度业绩超预期并上调全年EPS指引
当前推文只是Revvity二季度业绩与指引的社媒转述，同一具体财报催化已在10:11 UTC由IR源处理过。
📄 原文Wall St Engine@wallstengine↗ 原文
REVVITY $RVTY Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $711M (Est. $709M) 🟢; +4% YoY 🔹 Adj. EPS: $1.41 (Est. $1.22) 🟢; +19%…
不做 Revvity（RVTY.US）
同一Revvity二季度业绩催化已在10:11 UTC由IR源处理并产出决策，当前Wall St Engine推文仅为重复转述，不再重复推卡或建仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 medium
关键理由
- 当前推文只是Revvity二季度业绩与指引的社媒转述，同一具体财报催化已在10:11 UTC由IR源处理过。
- 事件本身偏正面：收入711百万美元略高于预期、调整后EPS 1.41美元明显高于预期，全年调整后EPS指引5.30-5.40美元高于一致预期5.27美元。
主要风险
- 重复转述不应再次推卡或重复下单，避免同一财报催化被多个来源延长交易窗口。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 956 字
REVVITY $RVTY Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $711M (Est. $709M) 🟢; +4% YoY
🔹 Adj. EPS: $1.41 (Est. $1.22) 🟢; +19% YoY
🔹 Diagnostics Revenue: $371M; +12% YoY
🔸 Divests China Immunodiagnostics Business
Raises FY26 Guide:
🔹 Revenue: $2.83B-$2.86B (Est. $2.86B) 🟡
🔹 Organic Revenue Growth: 4-5%
🔹 Adj. EPS: $5.30-$5.40 (Est. $5.27) 🟢
Segment Net Revenue:
🔹 Diagnostics: $371M; +12% YoY
🔹 Life Sciences: $359M; -2% YoY
Other Q2 Metrics:
🔹 Adjusted Operating Margin: 28.9%; +230 bps YoY
🔹 Pro Forma Organic Revenue Growth: +3%
Comments:
🔸 “Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,”
🔸 “As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.”
🔹 Revenue: $711M (Est. $709M) 🟢; +4% YoY
🔹 Adj. EPS: $1.41 (Est. $1.22) 🟢; +19% YoY
🔹 Diagnostics Revenue: $371M; +12% YoY
🔸 Divests China Immunodiagnostics Business
Raises FY26 Guide:
🔹 Revenue: $2.83B-$2.86B (Est. $2.86B) 🟡
🔹 Organic Revenue Growth: 4-5%
🔹 Adj. EPS: $5.30-$5.40 (Est. $5.27) 🟢
Segment Net Revenue:
🔹 Diagnostics: $371M; +12% YoY
🔹 Life Sciences: $359M; -2% YoY
Other Q2 Metrics:
🔹 Adjusted Operating Margin: 28.9%; +230 bps YoY
🔹 Pro Forma Organic Revenue Growth: +3%
Comments:
🔸 “Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,”
🔸 “As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。